272 related articles for article (PubMed ID: 19200858)
21. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
[TBL] [Abstract][Full Text] [Related]
22. Recent insights into the mechanism of action of glatiramer acetate.
Kala M; Miravalle A; Vollmer T
J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
[TBL] [Abstract][Full Text] [Related]
23. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
Trojano M; Paolicelli D; Tortorella C; Iaffaldano P; Lucchese G; Di Renzo V; D'Onghia M
Neurol Clin; 2011 May; 29(2):309-21. PubMed ID: 21439443
[TBL] [Abstract][Full Text] [Related]
24. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
Johnson KP; Ford CC; Lisak RP; Wolinsky JS
Acta Neurol Scand; 2005 Jan; 111(1):42-7. PubMed ID: 15595937
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
Stuart WH
Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
[TBL] [Abstract][Full Text] [Related]
26. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis.
Khan O; Shen Y; Bao F; Caon C; Tselis A; Latif Z; Zak I
J Neuroimaging; 2008 Jul; 18(3):314-9. PubMed ID: 18304034
[TBL] [Abstract][Full Text] [Related]
27. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
Carroll WM
Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
Rovaris M; Comi G; Rocca MA; Valsasina P; Ladkani D; Pieri E; Weiss S; Shifroni G; Wolinsky JS; Filippi M;
Mult Scler; 2007 May; 13(4):502-8. PubMed ID: 17483532
[TBL] [Abstract][Full Text] [Related]
29. Treatment of pediatric multiple sclerosis and variants.
Pohl D; Waubant E; Banwell B; Chabas D; Chitnis T; Weinstock-Guttman B; Tenembaum S;
Neurology; 2007 Apr; 68(16 Suppl 2):S54-65. PubMed ID: 17438239
[TBL] [Abstract][Full Text] [Related]
30. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
32. Long-term experience with induction treatment regimens in multiple sclerosis.
Le Page E; Edan G
J Neurol Sci; 2009 Feb; 277 Suppl 1():S46-9. PubMed ID: 19200867
[TBL] [Abstract][Full Text] [Related]
33. [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].
Kohriyama T; Higaki M; Matsumoto M
Nihon Rinsho; 2003 Aug; 61(8):1381-7. PubMed ID: 12962027
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of multiple sclerosis--current practice and future directions.
Tullman MJ; Lublin FD; Miller AE
J Rehabil Res Dev; 2002; 39(2):273-85. PubMed ID: 12051470
[TBL] [Abstract][Full Text] [Related]
35. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
Farina C; Weber MS; Meinl E; Wekerle H; Hohlfeld R
Lancet Neurol; 2005 Sep; 4(9):567-75. PubMed ID: 16109363
[TBL] [Abstract][Full Text] [Related]
36. Prospects of repair in multiple sclerosis.
Yong VW
J Neurol Sci; 2009 Feb; 277 Suppl 1():S16-8. PubMed ID: 19200859
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppression followed by immunomodulation.
Boggild M
J Neurol Sci; 2009 Feb; 277 Suppl 1():S50-4. PubMed ID: 19200868
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of clinical trials of multiple sclerosis therapies.
Freedman MS
Neurology; 2011 Jan; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
[TBL] [Abstract][Full Text] [Related]
39. Early treatment: PreCISe-ly what the patient needs.
Montalban X
J Neurol Sci; 2009 Dec; 287 Suppl 1():S2-6. PubMed ID: 20106344
[TBL] [Abstract][Full Text] [Related]
40. Azathioprine and methotrexate in multiple sclerosis.
Fernández O; Fernández V; De Ramón E
J Neurol Sci; 2004 Aug; 223(1):29-34. PubMed ID: 15261557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
